ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,832 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,404 shares during the period. Bank of New York Mellon Corp owned 0.59% of ANI Pharmaceuticals worth $6,845,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Thrivent Financial for Lutherans increased its holdings in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after buying an additional 299 shares during the period. Exchange Traded Concepts LLC boosted its holdings in shares of ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after acquiring an additional 310 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after acquiring an additional 412 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after purchasing an additional 579 shares during the last quarter. Finally, KBC Group NV lifted its position in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

ANIP has been the topic of several analyst reports. Guggenheim raised their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. StockNews.com upgraded shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective for the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Finally, Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 price target for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $79.75.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $191,776 in the last three months. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Price Performance

ANIP traded down $0.13 on Tuesday, reaching $64.22. 233,027 shares of the company's stock were exchanged, compared to its average volume of 238,208. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock's fifty day moving average price is $58.79 and its 200-day moving average price is $58.07. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81. The stock has a market cap of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.